{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-013736+%28AXITINIB%29&page=3", "query": { "intervention": "AG-013736 (AXITINIB)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-013736+%28AXITINIB%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG-013736+%28AXITINIB%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T18:11:37.429Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07123090", "title": "A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Metastatic Renal Cancer", "Renal Cell Carcinoma", "Advanced Clear Cell Renal Cell Carcinoma", "Kidney Cancer", "Translocation Renal Cell Carcinoma" ], "interventions": [ { "name": "Sasanlimab", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stephanie Berg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-11-24", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07123090" }, { "nct_id": "NCT04873895", "title": "TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms Malignant" ], "interventions": [ { "name": "Axitinib 5 MG", "type": "DRUG" }, { "name": "Hydroxychloroquine Pill", "type": "DRUG" }, { "name": "trans arterial chemoembolization", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-01-24", "completion_date": "2024-04-25", "has_results": false, "last_update_posted_date": "2024-04-26", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04873895" }, { "nct_id": "NCT03472560", "title": "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "Avelumab (MSB0010718C)", "type": "DRUG" }, { "name": "Axitinib (AG-013736)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2018-05-02", "completion_date": "2023-02-09", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 14, "location_summary": "Glendale, Arizona • Goodyear, Arizona • Phoenix, Arizona + 8 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472560" }, { "nct_id": "NCT02782403", "title": "Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia (CML)", "Blast Phase Chronic Myelogenous Leukemia (CML)", "Chronic Phase Phase Chronic Myelogenous Leukemia (CML)", "Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-03-20", "completion_date": "2019-11-11", "has_results": false, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782403" }, { "nct_id": "NCT01385059", "title": "Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "axitinib", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2011-10-28", "completion_date": "2013-10-09", "has_results": true, "last_update_posted_date": "2023-03-07", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01385059" }, { "nct_id": "NCT07227415", "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell", "Advanced Renal Cell Carcinoma", "Renal Cancer", "Renal Neoplasm", "Clear Cell Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Clear-cell Metastatic Renal Cell Carcinoma", "Carcinoma, Renal Cell Metastasis", "Advanced or Metastatic Renal Cell Carcinoma", "Carcinoma, Renal Cell, Advanced", "Metastatic Renal Cell Cancer", "Metastatic Renal Cell Carcinoma ( mRCC)", "Metastatic/Advanced Renal Cell Carcinoma" ], "interventions": [ { "name": "PF-08634404", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Casdatifan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2026-02-10", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 140, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 84 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227415" }, { "nct_id": "NCT01469546", "title": "Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Axitinib (AG-013736)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2012-01", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01469546" }, { "nct_id": "NCT00678392", "title": "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Neoplasms" ], "interventions": [ { "name": "Axitinib (AG-013736)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 723, "start_date": "2008-09-03", "completion_date": "2016-02-25", "has_results": true, "last_update_posted_date": "2019-01-09", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 161, "location_summary": "Burbank, California • Downey, California • Glendale, California + 103 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00678392" }, { "nct_id": "NCT05700461", "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Kidney Cancer" ], "interventions": [ { "name": "Implantable Microdevice (IMD)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Oliver Jonas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-12-01", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05700461" }, { "nct_id": "NCT02579811", "title": "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Cancer" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-12-30", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-03T18:11:37.429Z", "location_count": 4, "location_summary": "Duarte, California • Cleveland, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02579811" } ] }